Celebs in Parody Video Urge Support for Movember to Raise Prostate Cancer Awareness
In a lighthearted twist on a serious goal of raising awareness and funds for prostate cancer, the Movember Foundation is again encouraging gents to join glitterati in celebrating the moustache. The annual event is called Movember, a blending of the Australian-English...
Brachytherapy Beneficial in Low Risk Prostate Cancer
Low-dose-rate (LDR) brachytherapy with or without androgen deprivation therapy may be the optimal treatment option for men with T1c to T3a prostate cancer (PCa), according to a new retrospective study published in Oncology Letters. For full article click HERE.
FDA Approves Erleada to Treat Metastatic Castration-Sensitive Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation therapy (ADT). To read the full article...
Largest-ever African American Prostate Cancer Study Seeks Participants
African American men recently diagnosed with prostate cancer are being recruited across the U.S. for the largest-ever prostate cancer study in this ethnic group. The study is a joint effort by prostate cancer researchers and experts from around the country and will...
Prostate Cancer’s Risk and Mortality Dropping or Stabilizing
Prostate cancer’s incidence and deadliness has declined or stabilized in much of the world in recent years, with the greatest decrease in risk evident in the U.S., a study reports. Read full article here.
Patient Survey on Impact of Prostate Cancer
Men who are diagnosed with prostate cancer at later stages of the disease are more likely to say that their disease has affected several aspects of their life, including their self-esteem, how they share feelings with others, and how they feel about their sexual...
Bucking Landmark U.S. Recommendation, Oncologist Urges PSA Screening
Despite a United State Preventative Service Task Force 2012 conclusion that routine tests for prostate cancer are unnecessary, a prominent oncologist believes such screenings should be encouraged. Click HERE to read the full article.
Prostate Cancer Scoring Method May Not Accurately Predict Outcomes in Black Men
Black men diagnosed with prostate cancer are 2 times more likely to actually have a more aggressive, fatal form of the disease than those of other races, suggesting that the current prostate cancer score method may be underestimating the risk of death among black...
Top Ten Steps to Fight Prostate Cancer
If you have been diagnosed with prostate cancer, these steps will help you understand what to do next.
10-Year Survival of Young Low- and Intermediate-risk Prostate Cancer Patients Better with Radiation than Surgery
Radiation Therapy approaches — including brachytherapy and external beam radiation therapy (EBRT) — lead to better 10-year survival rates than prostate surgery in young patients with low- and intermediate-risk prostate cancer, a study shows. The research,...
Prostate Cancer Free Foundation Study Update
The Prostate Cancer Free Foundation has published an updated version of the comparative analysis study. The update represents the treatment outcomes of over 119,000 men. Click here for the update:
PSA TESTING CUTS DEATHS, Shows Value of Long Term Screening
The longest screening study on prostate cancer shows blood test measuring the levels of PSA, a well-known marker of prostate cancer, cuts deaths from the disease by nearly 30%. The study followed 20,000 men in Sweden for more than two decades and was featured...
Study Shows Radiation Treatments Delay Metastasis, Recurrence in Aggressive Prostate Cancers
A recent study shows that patients with aggressive forms of prostate cancer, who undergo radiation therapy- including external beam radiation therapy and brachytherapy- experience longer periods of time before metastasis or cancer...
Support the Foundation while you shop for the holidays
Black Friday and Cyber Monday are two of the busiest shopping days of the year. Support us when you shop on Amazon on Black Friday, Cyber Monday and the holiday season. Begin your Amazon shopping on this link: smile.amazon.com/ch/27-4434212 and Amazon donates to the...
75% of men with slow-growing prostate cancer fail to get appropriate follow-up
A recent study out of Australia found that nearly 3 out of 4 men with slow-growing prostate cancer, that chose to pursue active surveillance, are not receiving the appropriate follow-up to monitor the disease. These men are not getting the follow-up they need, and in...
3 in 4 Americans are Unaware Prostate Cancer Doesn’t Have Early Symptoms
When it comes to Prostate Cancer awareness, we have a ways to go here in the US. Recent study found that nearly 3 out of 4 Americans are unaware that early-stage prostate cancer has a lack of noticeable symptoms, and less than one-third know that men could receive...
Prostate Cancer Diagnosis – Do You Really Know “All” Your Treatment Options?
A Prostate Cancer diagnosis can be devastating and understanding the available treatment options can be overwhelming and is often more perplexing and confusing than the diagnosis itself. Leading to the confusion, there are many treatment options for prostate cancer,...
Early diagnosis is key to surviving prostate cancer
Dr. Gregory Merrick says the key to surviving prostate cancer is to undergo screening for early prostate cancer detection. That combined with a healthy lifestyle is key to men's health. You can read his whole interview here: "Early Diagnosis Remains Key to Surviving...
September is Prostate Cancer Awareness Month!
September is National Prostate Cancer Awareness Month. Did you know that one in six men will be diagnosed with prostate cancer during their lifetime. It's important to talk to your family and friends about the risk of prostate cancer, and the importance of screening....
Finland study finds how genetic mutation can cause aggressive forms of prostate cancer
Researchers at the University of Oulu in Finland, have found that a type of mutation in a single nucleotide plays a role in the development of aggressive prostate cancer. The study identified several key risk factors involved, and genetic predisposition was one of the...
Study finds nearly 3 out of 4 men on active surveillance are failing to get appropriate follow-up
The second most common cancer in men worldwide (after skin cancer) is still prostate cancer. Most cases diagnosed are slow growing, and may not require immediate treatment. Therefore, a lot of patients pursue active surveillance. According to a recent study in...
PCa Commentary
Expert Commentary On The Latest Prostate Cancer Topics
Written by Dr. Ed Weber
PCa Commentary is a well-researched, clearly presented commentary targeted to medical providers and others interested in current prostate cancer treatment. Each PCa Commentary edition offers an analysis of new developments in the field of prostate cancer with essays discussing and evaluating treatment management options for this disease.
PCa Commentary #139 Oligometastatic Prostate Cancer: Is it an Intermediate Stage of Cancer, and if so, How Should it be Treated?
The suggestion that a few (usually 3 - 5, i.e., ‘oligometastatic’) lesions at the time of biochemical failure after primary treatment might represent an indolent disease state with limited potential for additional spread. This hypothesis was first made in 1995 by...
PCa Commentary #138 Active Surveillance: Update and New Developments
The first study of active surveillance (AS) was started in 1996 at the University of Toronto byDr. Lawrence Klotz. It was first reported in the literature in 2002. In the ensuing 20 years AS has become increasingly accepted as a management approach to biopsy diagnosed...
PCa Commentary #137 Radium-223 (‘Xofigo’): A Radioisotope Treatment for Bone Metastases — Where Does It Fit in the Management of Prostate Cancer?
Radium-223 combined with Lupron demonstrated a median 3.6 month extension of overall survival, compared to the placebo (14.9 v 11.3 months). This was the outcome of a 928 man randomized trial (ASYMPCA) in asymptomatic or mildly symptomatic men with...
PCA Commentary #136 Natural History of Prostate Cancer
The Natural History of Prostate Cancer and the Prognostic Utility of PSA Doubling Time. We are indebted to UroToday for making available online the informative presentation at ASCO 2019 by Dr. Catherine Marshall: “Outcomes of Men with Recurrent MO [metastasis...
PCa Commentary #135 Managing PCa Recurrence Following Radiation Therapy
Managing PSA Recurrence Following Primary Radiation Therapy: Evolving Regimens for Focal Treatment Biochemical recurrence following primary irradiation is relatively common. “A recent series of 2694 patients treated with doses above 78 Gy revealed 10-year...
PCa Commentary #134 Radioligand Therapy – The “VISION” Protocol: A treatment opportunity for men with late-stage metastatic castration-resistant prostate cancer.
Radioligand therapy (RLT) - i.e. PSMA directed endoradiation with Lutetium-177 - has been developed to the extent that it is a realistic option for men with late stage, heavily pretreated metastatic castration-resistant prostate cancer. The national protocol...
PCa Commentary #133 GENOMIC SEQUENCING FOR PROSTATE CANCER – Which Men Gain a Clinical Benefit from Genomic Testing.
The commonly cited goal of ‘personalized medicine’ in regards to treatment selection based on genomic testing is early in the ‘work in progress’ stage. Breathtaking advances in next generation sequencing are very promising, but currently there are only limited options...
PCa Commentary #132 Resistance to Therapeutic Agents Targeting the Androgen Receptor and Insights into Sequencing Treatments for Optimal Outcomes
Ever since the first orchiectomy for metastatic prostate cancer in 1941 researchers and clinicians have been determinedly trying to restrain the androgen receptor (AR) by manipulating its hormone environment. But this wily adversary, like Houdini, after initial...
PCa Commentary #131: ENZALUTAMIDE (‘XTANDI’): AN UPDATE — The Many Faces of Enzalutamide
Enzalutamide (ENZ) was reviewed in the PCa Commentary of March/April 2014. Many important developments have taken place since then. This Commentary will discuss the current indications for ENZ and new studies of ENZ as monotherapy. A subsequent Commentary will address...
PCa Commentary #130: Ga68-PSMA-11 PET/CT Scanning at Initial Diagnosis for High-Risk Prostate Cancer: What is missed by conventional staging and does it matter.
This Commentary benefitted from a review and suggestions from Thomas Hope, MD, Associate Professor of Abdominal Imaging and Nuclear Medicine, UCSF THE FIRST QUESTION likely, is why present a Commentary about the Gallium68-PSMA-11 PET/CT scan. Its...
UNDERSTANDING PROSTATE CANCER
What is Prostate Cancer?
What is Prostate Cancer, the Symptoms, Risk Factors? What does the Prostate do, where is it located?
Diagnosed with Prostate Cancer?
What tests confirm the presence of prostate cancer? Learn how doctors diagnose prostate cancer.
Treating Prostate Cancer.
Patients have options when it comes to the prostate cancer treatments. Learn about your options.
Prostate Cancer Surgery or Radiation ???
Need Treatment? YOU NEED THIS STUDY! This fifteen year study compares treatment success rates, following 119,000+ patients treated for prostate cancer, to see who became Prostate Cancer Free. Treated once. No more treatment. No recurrence. Get your copy of the study to discuss with your family and Doctor.
Help Others Choose the Best Treatment!
The Prostate Cancer Free Foundation, reviews the results of hundreds of thousands of men treated for prostate cancer. Tracking them for years. This information is available to you, and others like you, to help find the best prostate cancer treatment. This work takes time, effort, resources all of it done by volunteers. Please help us continue. Please Donate!